Bliss GVS Pharma to announce Q2 and H1 2025 financial results

Bliss GVS Pharma Limited announced a Board of Directors' meeting scheduled for Thursday, November 06, 2025. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. This intimation was made on October 29, 2025, to comply with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code, the trading window for designated persons and their immediate relatives closed on October 01, 2025. It will remain closed until 48 hours after the financial results for the quarter and half year ended September 30, 2025, are announced.